On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

In February 2022, the Finnish Coordinating Center for Health Technology Assessment announced the release of the seven accomplished rapid hospital assessments performed by the Helsinki, Tampere, and Oulu University Hospital. The accomplished rapid HTAs concern the diagnostic imaging, e-Health, endocrine, endoscopy, men’s health, neuromodulation technology groups.

On February 16, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) has published the decisions which recommended the transfer to standard care for three completed projects. The projects relate to the prevention of antibiotic resistance, improvement of healthcare in socially disadvantaged areas, and misuse of control colonoscopies in Germany.

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

On February 08, 2022, the Reimbursement Commission of the Social Security Institution released an updated version of the Healthcare Implementation Communique. The main changes relate to the increase in reimbursement fees of services and medical devices by approximately 35-75%.

On February 14, 2022, the Danish Treatment Council (Behandlingsråd), a new body for assessing treatments and health technologies that became fully operational in late May 2021, has announced its symposium, which will take place in Aalborg on May 11, 2022.

In February 2022, two more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, thirty health apps are now available at the DiGA Directory.

A new temporary reimbursement framework for remote consultations is planned to be implemented in Belgium in spring 2022.

On February 04, 2022, NHSX announced merging with NHS Digital into the new Transformation Directorate at NHS England. NHSX's mission will remain the same - to drive the digital transformation of the NHS and social care.

On February 15, 2022, the preliminary version of the DRG manual for 2022 was published in France. Introduced changes (new DRGs, change of DRG logic) concern surgical procedures on the breast, interventions for malignant skin tumors, interventions of excision and grafting on the skin and subcutaneous tissue, spondyloplasties.

The Council for Choices in Health Care in Finland (PALKO) has discontinued the development of recommendations concerning companion diagnostic tests. The respective preparations were completed in November 2021.

On January 18, 2022, the Ministry of Health has awarded the Framework Agreement for the acquisition of 81 linear accelerators included in the High-End Technology Equipment Investment Plan. Furthermore, the National Institute of Health Management (INGESA) has also initiated the processing of the Framework Agreement that will facilitate the acquisition of the equipment in the fields of interventional cardiology, interventional vascular radiology, interventional neurovascular, digital brachytherapy, computed tomography, magnetic resonance imaging, PET-CT, SPECT-CT.